Aegerion Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 93   

Articles published

AEGR 21.81 +0.44 (2.06%)
price chart
Why Aegerion Pharmaceuticals, Inc. Stock Collapsed in October
What: Shares of Aegerion Pharmaceuticals (NASDAQ: AEGR ) , a biopharmaceutical company focused on developing drugs to treat rare diseases, collapsed in October and lost 40% of their value, based on data from S&P Capital IQ, after the company ...
Front Runners: Tesla Motors (TSLA), Aegerion Pharmaceuticals (AEGR), AAC ...  Wall Street Pit
Aegerion Pharmaceuticals Acquires Myalept(TM) From AstraZeneca  GlobeNewswire (press release)
Related articles »  
Aegerion Pharmaceuticals (AEGR) Stock Downgraded Today at Jefferies
"We rate AEGERION PHARMACEUTICALS INC (AEGR) a SELL. This is driven by a few notable weaknesses, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared ...
Aegerion Falls On Disappointing Earnings  Bidness ETC
Aegerion Pharmaceuticals Announces Third-Quarter 2014 Financial Results  CNNMoney
Related articles »  
Aegerion Pharmaceuticals (AEGR) Is Today's Dead Cat Bounce Stock
Aegerion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapies for patients with debilitating rare diseases in the United States.
Aegerion Pharmaceuticals to Announce Third-Quarter 2014 Financial Results on ...  MarketWatch
Notable Movers- Aegerion Pharmaceuticals, (NASDAQ:AEGR), Dean Foods Co ...  Techsonian (press release)
Related articles »  
Aegerion Downgraded As Stock Sheds 41% On Disappointing Q3 Results
Aegerion Pharmaceuticals, Inc. (AEGR) posted disappointing earnings in after-hours Thursday, leading many analysts to downgrade the stock the following morning.
Aegerion Pharmaceuticals Inc. (AEGR) Sank To A New Low After Outlook ...  RTT News
Related articles »  
Aegerion Pharmaceuticals, Inc. (AEGR): Broadfin Boosts Stake Getting on Board ...
Kevin Kotler's New York-based fund Broadfin Capital has boosted its position in Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR).
Related articles »  
Aegerion Pharmaceuticals, Inc. (AEGR): Steve Cohen's Point72 Asset ...
Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) is a $850 million market cap, biopharmaceutical company that develops therapies for patients with debilitating rare diseases.
Related articles »  
Will Aegerion (AEGR) Disappoint This Earnings Season?
Teva will report third-quarter results on Oct 30 before market opens. Vertex Pharmaceuticals Inc. (VRTX - Analyst Report) has an Earnings ESP of +28.07% and holds a Zacks Rank #3 (Hold).
Related articles »  
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program
CAMBRIDGE, Mass., Nov. 12, 2014 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare ...
Investor Company News: Aegerion Pharmaceuticals , Advisory Board Company  Markets Insider
Related articles »  
Notable Stocks - Aegerion Pharmaceuticals, Inc.(NASDAQ:AEGR),Petroquest ...
Manhattan, NY- November 20, 2014 - (Techsonian) - Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) revealed that on November 3, 2014, Aegerion granted stock options to purchase an aggregate of 35,000 shares of common stock to nine new employees ...
Commit To Buy Aegerion Pharmaceuticals At $15, Earn 17% Using Options
Investors eyeing a purchase of Aegerion Pharmaceuticals Inc (Symbol: AEGR) stock, but cautious about paying the going market price of $23.29/share, might benefit from considering selling puts among the alternative strategies at their disposal.
Related articles »